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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.033Leukocytes attach to vascular endothelial cells at the site of inﬂammation via a series of intercellular
adhesive interactions. In a separate step in leukocyte extravasation, transendothelial migration is regu-
lated bymolecules that play no role in the preceding steps of tethering, rolling, adhesion, and locomotion.
Transendothelial migration itself can be dissected into a series of distinct interactions regulated
sequentially by molecules concentrated at the endothelial cell border; these include platelet/endothelial
cell adhesion molecule, poliovirus receptor (CD155), and CD99. These molecules are components of the
lateral border recycling compartment (LBRC), a perijunctional network of interconnected tubulovesicular
membrane that trafﬁcs to surround the leukocyte as it passes across the endothelial cell. This targeted
recycling of LBRC requires kinesin to move the membrane along microtubules, and interfering with LBRC
trafﬁcking blocks transmigrationof neutrophils, monocytes, and lymphocytes. The LBRC is also recruited to
mediate transcellular migration when that occurs. Movement of the LBRC is coordinated with events on the
luminal surface, such as clustering of intercellular adhesionmolecule 1 and vascular cell adhesionmolecule
1 under the migrating leukocyte, as well as movement of vascular endothelial cadherin and its associated
catenins out of the junction at the site of transendothelial migration. How these events are coordinated is
not known, but their regulation shares common signaling pathways that may serve to connect these steps.
(Am J Pathol 2014, 184: 886e896; http://dx.doi.org/10.1016/j.ajpath.2013.12.033)Supported by NIH grants R01-HL046849 and R37-HL064774.
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The Point of No Return in the Inﬂammatory Response
The inﬂammatory response, the body’s rather stereotyped
response to tissue damage of any kind, evolved to heal
wounds and ﬁght infections. However, recent improve-
ments in human health mean that we are living long
enough to experience the other side of the double-edged
sword of inﬂammation. There has not been time enough on
an evolutionary scale to select against the baggage that
comes with our ability to heal wounds and kill foreign
microorganisms. Inﬂammation is at the root of virtually allstigative Pathology.
.pathology. Thus, there has been great interest in under-
standing how inﬂammation is regulated and so to design
pharmaceutical and other interventions to control it.
Regulation of Transendothelial MigrationAcute inﬂammation involves soluble and cellular media-
tors that act over the ﬁrst minutes to hours of the inﬂamma-
tory response. At the site of inﬂammation, generally in
postcapillary venules, inﬂammatory mediators such as his-
tamine secreted by mast cells cause local endothelial
permeability, allowing preformed agents such as antibody
and complement to cross endothelial junctions into the tissue.
It is a common misconception that the increase in vascular
permeability is causally related to increased leukocyte
extravasation. Although these phenomena are both part of the
acute inﬂammatory response, peak vascular leakage occurs
well before leukocyte extravasation begins.1 Furthermore,
the gaps between endothelial cells created by these agents
measure only a few hundred angstroms (tens of nanometers),
not nearly large enough to allow white blood cells to pass
through. Other mechanisms are therefore required to allow
leukocytes into the area. Recent in vivo studies demonstrate
conclusively that vascular permeability and transendothelial
migration (TEM) are separate phenomena. Mice made
genetically deﬁcient in the actin-bundling protein cortactin
have vessels that are constitutively leaky and have an exag-
gerated vascular leak response to inﬂammation. However,
leukocyte emigration in these mice is actually reduced,
compared with wild-type littermates, because of reduced
intercellular adhesion molecule 1 (ICAM-1) clustering and
therefore reduced leukocyte adhesion and transmigration.2
The Multistep Extravasation Paradigm
The process of leukocyte extravasation has been broken
down into a series of adhesive and signaling interactions
between leukocytes and endothelial cells. Over the past two
decades, we have learned much about the cellular and mo-
lecular interactions that take place during this process.3e5
Histamine, thrombin, and other mediators of acute inﬂam-
mation stimulate exocytosis of WeibelePalade bodies from
endothelial cells, bringing P-selectin to the luminal surface.
The same increased vascular permeability that allows
plasma to leave the bloodstream causes local hemoconcen-
tration, which decreases the rate of blood ﬂow, allowing
selectin ligands expressed on the surface of the slowly
moving leukocytes to contact P-selectin and thus causing
the leukocytes to roll along the luminal surface. Rolling
brings the leukocytes close enough for their chemokine re-
ceptors to be activated by chemokines attached to the
endothelial surface via glycosaminoglycans. Under certain
conditions, other cell-surface receptors (eg, platelet-
activating factor receptor) bind to and are activated by
nonchemokine ligands expressed on the endothelial surface.
The activated receptors, through an inside-out signaling
cascade, activate leukocyte integrins for tighter adhesion to
endothelial surface. This leads ﬁrst to slow rolling on the
endothelium and then to ﬁrm arrest. Attached leukocytes
then locomote over the endothelial surface, using primarily
the b2 integrin CD11b/CD18 bound to ICAM-1
6e8 to reach
the junction. When viewed in vivo by intravital microscopy,The American Journal of Pathology - ajp.amjpathol.orgleukocytes are sometimes seen to migrate over several
endothelial cells (occasionally migrating against the direc-
tion of blood ﬂow) before they cross the endothelial cells,
usually passing through the endothelial junctions.
Rolling, activation, adhesion, and locomotion (intra-
luminal crawling) are all critical for leukocyte extravasation,
but these are reversible. In fact, most leukocytes that enter a
venule at the site of inﬂammation do not roll, most leuko-
cytes that roll do not adhere, and most that adhere do not
extravasate.9 However, once leukocytes make the commit-
ment to cross the endothelium into the tissue, with notable
exceptions,10 they never go backdat least not as the same
type of cell. And all of the good, the bad, and the ugly of
inﬂammation takes place once leukocytes cross blood ves-
sels. Thus, diapedesis or TEM is a logical process to study if
one hopes to control an ongoing inﬂammatory response.5,11
Diapedesis Is a Distinct Step in TEM
Electron microscopy studies of leukocytes in the process of
TEM show that the leukocytes squeeze in amoeboid fashion
between tightly apposed endothelial cells.12,13 Neutrophils
have the pharmacological armamentarium to blow a hole in
the vessel wall, but instead of barging in like a SWAT team,
they sneak in like spies, minimizing leakage of vascular
contents into the interstitial tissues. It was this tight apposi-
tion of leukocyte and endothelial cell membranes that fasci-
nated me. Considering that it takes only 1 to 2 minutes for the
leukocyte to completely traverse the endothelial border
in vitro6 or in vivo,10 this suggests that very specialized
membraneemembrane interactions are taking place. In the
1980s, when I started my training, leukocytes were assumed
to direct the inﬂammatory response. They were known to
have receptors for speciﬁc chemoattractants as well as
adhesion molecules (later deﬁned as integrins) promoting
their migration. Endothelial cells were assumed to serve only
as a relatively inert Teﬂon-like lining to blood vessels, pre-
venting blood from clotting. However, the ability to culture
endothelial cells in vitro, which was pioneered at the Gim-
brone and Jaffe laboratories in the early 1970s,14,15 catapulted
vascular biology into the molecular era. It soon became
apparent that endothelial cells play a major role in the regu-
lation of most metabolic and physiological processes,
including blood pressure, glucose metabolism, thrombosis,
hemostasis, and inﬂammation. I wondered whether there were
speciﬁc endothelial molecules at the junctions important for
intercellular adhesion that regulate diapedesis, in the sameway
that the selectins and vascular cell adhesion molecule 1
(VCAM-1) and ICAM-1 on the apical surface are important
for leukocyte rolling and adhesion, respectively.16e19
Adhesion Molecules at the Junction with Unique Roles
in TEM
Monoclonal antibodies (mAbs) were made against endothelial
cells and selected for those that bound to antigens concentrated887
Mullerat endothelial cell borders. This strategy yielded mAbs that
recognize platelet endothelial cell adhesion molecule
(PECAM),20 vascular endothelial cadherin (VE-cadherin),21
and CD99.22 Blocking antibodies against the homophilic
interaction domain of PECAM, when added to either leuko-
cytes or endothelial cells in in vitro transmigration assays,
block TEM as completely as adding the antibodies to both cell
types at the same time, demonstrating the homophilic nature of
this interaction.23 Moreover, blocking PECAMePECAM in-
teractions has no effect on adhesion of leukocytes to23 or
locomotion on6 the endothelium. Removing the PECAM
blockade allows leukocytes to resume transmigration.23 These
experiments demonstrate that TEM is a distinct step in
leukocyte emigration that is molecularly dissectable from the
other steps. This ﬁnding has been replicated inmanymodels of
acute inﬂammation in vivo, and antibodies or soluble PECAM-
Fc chimeras that interfere with the homophilic interaction
of mouse PECAM (or genetic deletion of PECAM) block
inﬂammation in peritonitis,24,25 dermatitis,26 arthritis,27 exper-
imental autoimmune encephalitis,28 and antigen-speciﬁc T-cell
trafﬁcking in the central nervous system.29 Anti-PECAM
antibodies also block inﬂammation in various cat and rat
models (reviewed in ref. 9).
This role for PECAM in extravasation has been borne out
in all mouse strains tested except for C57BL/6 mice,30,31
which have a way to bypass the requirement for PECAM
for leukocyte extravasation. In the thioglycollate peritonitis
model, this trait maps to a small region on the short arm of
mouse chromosome 2.31 It is important to note that PECAM
has a separate immunosuppressive role in T cells,32,33 and
knocking out PECAM in C57BL/6 mice may in some cases
lead to hyperactive immune responses.34,35 Thus, animal
models using PECAM-deﬁcient mice of the C57BL/6 strain
that are measuring both the afferent and efferent limbs of the
immune response may show enhanced disease.36 Never-
theless, observations with PECAM led the way for discov-
ery of other endothelial cell molecules that regulate TEM.
Some of these, such as CD99 and poliovirus receptor
(CD155), appear to function only in the process of diape-
desis. Others, such as ICAM-1, ICAM-2, VCAM-1, and a
number of the junctional adhesion molecule (JAM) family
members, have functions in earlier steps in the pathway, as
well as potential roles in diapedesis.5,11Diapedesis Is a Multistep Process
CD99 is another molecule expressed on both leukocytes and
endothelial cells. Similar to PECAM, homophilic interaction
between leukocyte CD99 and endothelial CD99 is required
for TEM, and blocking either side blocks TEM as efﬁciently
as blocking both.23,37 Furthermore, like PECAM, CD99 has
no effect on the earlier stages of rolling, adhesion, or
locomotion.
We have examined the interactions of leukocytes with
endothelial cells when TEM is blocked by either PECAM or888CD99. When PECAMePECAM interactions are blocked,
whether by mAb, soluble decoy PECAM-Fc, or PECAM
knockout, leukocytes are arrested on the apical surface of
the endothelial cell. They remain tightly adherent and crawl
over the endothelium, usually along the junctions, probing
with lamellipodia but unable to transmigrate.6,23 This was
observed by both scanning and transmission electron mi-
croscopy and also on living cells in vitro. This phenotype is
also observed by intravital confocal microscopy in vivo
(unpublished data). By contrast, when CD99 is blocked,
leukocytes are arrested partway through the junction with
the leading edge below the endothelial monolayer and the
trailing uropod on the apical surface.22 Observed in living
cells in vitro, the leukocytes are seen to extend further into
the junction but then retract part of the way back out as they
migrate along the endothelial borders, unable to complete
transmigration.37 This unusual phenotype is also observed
in vivo (unpublished data).
The two different morphologies suggest that PECAM and
CD99 control different steps in TEM. Alan Schenkel in my
research group took advantage of the fact that the blockade of
TEM by both anti-PECAM and anti-CD99 mAbs is reversible.
The block to TEM with anti-PECAM could be removed, and
TEM could be subsequently blocked by anti-CD99. However,
if TEM were ﬁrst blocked with anti-CD99 and this block sub-
sequently removed, TEM could no longer be blocked by anti-
PECAM.22 This demonstrates that PECAM functions at a step
upstream of CD99 and suggests that TEM can be dissected into
at least two steps, controlled by two separate molecules (but
begging the question of whether there are other molecules
controlling steps in TEM intermediate or distal to these).
Recently, David Sullivan and Michael Seidman38 in my
research group showed that poliovirus receptor (CD155),
another molecule at the endothelial borders, regulates a step
in TEM in between those regulated by PECAM and CD99.
Using the same sequential blocking technique as used for
CD99, they showed that monocytes released from a block in
TEM due to PECAM could still be blocked by antibodies
against CD155 or against its monocyte ligand, DNAM-1
(CD226), and monocytes released from a block in TEM
due to anti-CD155 or antieDNAM-1 antibodies could still
be blocked by anti-CD99, although these antibodies could
not block TEM of monocytes released from blockade in
TEM due to anti-CD99.38
CD99 is important for leukocyte extravasation in vivo, as
demonstrated by monoclonal39 and polyclonal40 antibody
blocking experiments. Similarly, other molecules implicated
in TEM through in vitro experiments, such as CD47 and
JAM-A, have been validated in vivo.41e43The Lateral Border Recycling Compartment
How do these molecules promote TEM? The paradigm
initially was that proinﬂammatory cytokines such as IL-1 or
tumor necrosis factor (TNF) up-regulate expression ofajp.amjpathol.org - The American Journal of Pathology
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However, such treatments change neither the expression
level nor the apparent distribution of PECAM or CD99.22
Zahra Mamdouh and Xia Chen44 found that approxi-
mately one third of the PECAM at the endothelial cell
border is present in a reticulum of membrane within the
endothelial cell close to the borders. This compartment is
unique. Although PECAM is internalized into this
compartment, it is distinct from the endocytic recycling
pathway of transferrin. Ultrastructurally, using horseradish
peroxidase (HRP)elabeled anti-PECAM mAb, they found
that at 37C anti-PECAM is brought into these parajunc-
tional arrays of 50-nm-diameter vesicle-like structures that
are connected to each other and connected to the cell border
at intervals. These structures often appear to be many
vesicle diameters away from the border, but biochemical
experiments demonstrate that they are all connected to each
other and to the junction (Figure 1). Although resembling
caveolae, they are a distinct set of vesicle-like structures, as
shown by numerous biochemical and immunohistologic
experiments.44 Not only is PECAM in this compartment,
but also other molecules implicated in TEM, such as CD99,
JAM-A, and CD155.38,46 Interestingly, although VE-
cadherin is seen along the endothelial borders, it does not
enter this compartment.46
Membrane from the junction is internalized rapidly into
this compartment, but the total levels of PECAM, CD99, and
the other molecules remain constant. We hypothesized that
the internalized membrane was recycled. At 4C, antibody
penetrated through the entire junction, but it did not enter this
compartment. Stereologic analysis shows that there was just
as much membrane in this compartment as there was at 37C,
but it was inaccessible. We developed a way to label the
membrane as it returns to the surface, based on the fact that
the compartment is inaccessible to the antibody at 4C.When
the temperature is increased, membrane from the compart-
ment is detected back on the surface within 5 minutes, and it
returns with a half-time of approximately 10 minutes, being
distributed randomly and evenly along the cell.46 Because of
the rapid and continuous ﬂux of membrane between theFigure 1 The LBRC as observed by immunoelectron microscopy.
Horseradish peroxidaseelabeled nonblocking anti-PECAM mAb was incu-
bated with human umbilical vein endothelial cells for 1 hour at 37C to
label PECAM in the junction as well as within the LBRC. After ﬁxation, the
location of the antibody was revealed by incubation with DAB and H2O2.
45
The interconnected vesicle-like structures of the LBRC can be seen budding
off the intercellular junction (arrowheads), interconnected in cisternae
(white arrows), or as apparently individual vesicles (black arrows). Scale
bar Z 500 nm.
The American Journal of Pathology - ajp.amjpathol.orgendothelial cell border and the compartment, we refer to this
as the lateral border recycling compartment (LBRC).47
Similar vesicles are also seen in mouse postcapillary ve-
nules in situ (unpublished data).
The LBRC Is Critical for Paracellular Transmigration
During TEM, the membrane from the LBRC is redirected.
Instead of returning evenly along the cell junction, it trafﬁcs
to the site where the leukocyte is transmigrating. The mem-
brane surrounding the transmigrating leukocyte is enriched
with membrane from the LBRC for the entire duration of its
passage (Figure 2). We call this process targeted recycling of
the LBRC. It is not just an epiphenomenondit appears to be
the sine qua non for transmigration.
Everything that we can do to block targeted recycling
blocks TEM. Interfering with leukocyte and endothelial cell
PECAMePECAM interactions blocks targeted recycling
and TEM.44 The LBRC is trafﬁcked along cortical micro-
tubules, so depolymerizing microtubules or blocking kinesin
molecular motors under proper experimental conditions
selectively blocks targeted recycling of the LBRC and
blocks TEM.47 The appearance of the blocked leukocytes in
all cases is the same. There is no effect on adhesion or
ability to migrate to the endothelial cell border; leukocytes
are arrested over the junctions and are unable to initiate
TEM.47 Mutating tyrosine 663 on the cytoplasmic tail of
PECAM blocks the ability of PECAM to enter and exit the
LBRC and to engage in targeted recycling. Cells in which
native PECAM is replaced with PECAM Y663F are unable
to support TEM, but normal levels of TEM can be rescued
by re-expressing wild-type PECAM.48
Antibodies against endothelial cell PECAM, CD155, and
CD99 block TEM, but only when added at 37C, conditions
under which they enter the LBRC.22,23,38 If the same anti-
bodies are added to endothelial cells at 4C, conditions
under which they saturably bind to all of their antigens
present at the junction but do not enter the LBRC, there is
no blockade of TEM when the unbound antibody is washed
away and leukocytes are added at 37C.22,23,38 Thus, it is
possible that only the fraction of junctional adhesion mol-
ecules within the LBRC is required for TEM.
The LBRC Is Critical for Transcellular Transmigration
Targeted recycling of the LBRC seems to be necessary for
TEM of neutrophils, monocytes, and lymphocytes under all
conditions testeddeven conditions in which we could not
block TEM by anti-PECAM antibodies. However, what
highlights the importance of the LBRC in TEM is the
exception that proves the rule. Greater than 90% of leuko-
cyte TEM takes place at endothelial cell borders, but under
certain conditions leukocytes can migrate through the
endothelial cell cytoplasm in what is called transcellular
migration. Under certain in vitro conditions, up to 30% of
neutrophils could be made to migrate transcellularly.49,50889
Figure 2 Targeted recycling of the LBRC during TEM. Two monocytes
caught in the act of TEM by paraformaldehyde ﬁxation. The monolayer was
stained with antibodies to VE-cadherin (green), to mark the cell junctions;
to recycling LBRC (red), to show targeted recycling; and to CD18 (blue), to
visualize the monocytes. Note the gap in VE-cadherin staining and the
enrichment of recycling LBRC where the leukocytes are passing across the
endothelial cells (arrows). An orthogonal view of one of the transmigration
events (XZ plane, shown below the merged image) shows a collar of LBRC
around the migrating monocyte. The level of the endothelial monolayer is
indicated by a broken line. Scale bar Z 10 mm.
MullerGenerally, these are conditions in which the leukocyte is
activated directly by a chemokine or other agent exposed to
it on the apical surface of cytokine-activated endothelium.
Zahara Mamdouh and Alexei Mikhailov46 found that, dur-
ing transcellular migration, the LBRC migrates from the
endothelial border to surround the leukocyte for the duration
of its passage. Microtubule depolymerization, which pre-
vents movement of the LBRC, blocks both transcellular and
paracellular transmigration. Furthermore, anti-PECAM or
an anti-CD99 mAb can block transcellular migration once it
has begun, even though these molecules are not present on
the apical surface of the endothelial cells.46 Thus, the LBRC
trafﬁcs to wherever the leukocyte is transmigrating, even if
it is far from the endothelial border.
Other Regulators of TEM
So far, I have highlighted the focus in my research group on
the molecular mechanisms in the endothelial cell that
regulate TEM. There are other equally important molecules
and mechanisms at work in endothelial cells that regulate
TEM. Some of these are outlined below, to put our work
into context.
ICAM-1 and VCAM-1 Clustering
As a prelude to TEM, ICAM-1 and VCAM-1 cluster under
the leukocyte as it approaches the junction.51e53 Clustering
of ICAM-1 requires c-Src-dependent phosphorylation of
cortactin to start the remodeling of actin54,55 and to
perpetuate ICAM-1 clustering,5 along with joining of tet-
raspanin molecules to these clusters.56 Although it is not
universally observed, under certain in vitro conditions the
apical surface membrane appears to extend upward, to
partially envelop the leukocyte during TEM.50,57 These so-
called transmigratory cups are enriched in ICAM-1,
VCAM-1, and tetraspanins overlying a core of actin
ﬁlaments.49,58
Clustering of ICAM-1 induces Src phosphorylation,59
which is required for several steps in TEM38,54,60 (in890addition to the role in activating cortactin). ICAM-1
clustering also activates RhoA.61,62 Interestingly, just like
the self-enforcing interactions between cortactin phosphor-
ylation and ICAM-1 clustering, active RhoA enhances
ICAM-1 clustering.63 RhoA in turn activates Rho kinase
(ROCK), which inactivates protein phosphatase 1c and in-
hibits the inactivation of myosin light chain kinase (MLCK).
The net result is promotion of the activity of MLCK, which
tugs on actin ﬁlaments and effectively loosens the junctions.
Calcium Signaling
Elevation of endothelial cytosolic free calcium ion con-
centration ([Caþ2]i) is known to be required for trans-
migration to proceed. Blocking the ability of endothelial
cells to ﬂux calcium using a cell-permeable calcium chelator
leads to the same phenotype as blocking PECAM, in which
leukocytes arrest on the apical surface of the endothelium,
tightly adherent but unable to transmigrate.64 It has been
demonstrated that increased [Caþ2]i leads to activation of
MLCK through calmodulin (CaM).65 The source of the
increased [Caþ2]i is not clear, although VCAM-1 clustering
and cross-linking of P- or E-selectin66 have been implicated.
MLCK activates nonmuscle myosin in endothelial cells for
interaction with actin ﬁlaments, leading to tension devel-
opment within the cell, which likely promotes loosening of
the junctions.
Movement of VE-Cadherin
Although we have been focusing on the recruitment of the
LBRC to the site of transmigration, there is extensive evi-
dence that certain membrane proteins, in particular VE-
cadherin and its associated catenins, transiently leave the
site of TEM.67,68 Under resting conditions, vascular endo-
thelial cell protein tyrosine phosphatase (VE-PTP) associ-
ates with VE-cadherin, the main adhesion molecule of
endothelial cell adherens junctions, and maintains it in a
state of reduced phosphorylation at the endothelial junc-
tions.69 Leukocyte adhesion to activated endothelial cells
triggers dissociation of VE-PTP from VE-cadherin, allow-
ing phosphorylation of the latter.69,70 A recent study71
suggests that this occurs through a signaling pathway in
which VCAM-1 activates Rac1, which activates endothelial
NADPH oxidase, the reactive oxygen metabolites of which
activate Pyk2. Pyk2 is hypothesized to phosphorylate an
alternative substrate of VE-PTP, which then displaces
binding to VE-cadherin.
Displacement of VE-PTP from VE-cadherin is the ﬁrst
step in its dissociation from the membrane. This allows
access to VE-cadherin by protein kinases. VE-cadherin is
tethered to the cortical actin cytoskeleton by a-catenin, to
which it binds via p120 and b-catenin.72 Phosphorylation of
VE-cadherin on tyrosine 658 by Src and on tyrosine 731 by
Pyk2 inhibits binding of p120 and b-catenin, respectively.
Dissociation of VE-cadherin from p120 and b-cateninajp.amjpathol.org - The American Journal of Pathology
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teractions not only regulate endothelial cell permeability,
but also regulate TEM. Mutation of tyrosine residues 658 or
731 to phenylalanine inhibits the release of p120- and
b-catenin, maintains more VE-cadherin at the cell border,
and reduces TEM.72 This demonstrates that removal of VE-
cadherin from the endothelial cell border at the site of TEM
is not just an epiphenomenondit is a requirement for
transmigration. The relationship between the inﬂux of
membrane from the LBRC and the apparent removal of VE-
cadherin from the site of TEM is the subject of ongoing
study. In Figure 3, I summarize and try to integrate some of
the major adhesion and signaling events that occur during
the transmigration process.
Other Molecules Involved in TEM
Many molecules are reported to play a role in TEM, because
antagonizing these molecules blocks leukocyte migration in
transmigration assays. Many of these studies do not distin-
guish between a true block in diapedesis and a block in
leukocyte adhesion, chemotaxis, ability to migrate per se,
detachment from the underside of the endothelial cell,
migration across the extracellular matrix, or (in some assays)
migration through the pores of a ﬁlter support.73 However,
even discounting such ﬁndings, several other endothelial cell
molecules have been reported to play a role in mediating
TEM, in that blockade by antibodies or knockdown of these
molecules reduces TEM. In addition to PECAM, CD155,
CD99, and the recently reported CD99L2,74e76 these other
molecules include JAM-A,77,78 JAM-C,10,79 ICAM-2,43,80,81
CD47,82 MUC18 (CD146),83 activated leukocyte cell adhe-
sion molecule (ALCAM),84 nepmucin,85 and even the puri-
nergic receptor P2Y2.
86 Restoration of TEM by re-expressing
a candidate molecule after it has been knocked down is a
more reliable way to establish that the molecule plays a role
in transmigration than by simply knocking it down or
blocking its function. This has now been demonstrated with a
number of molecules.5 Nevertheless, to our knowledge,
PECAM is the only molecule demonstrated to play a role in
TEM by a true gain of function. Expression of PECAM inFigure 3 A uniﬁed schematic view of TEM. A: Clustering of ICAM-1 and
VCAM-1 through engagement of their leukocyte integrin counter-receptors
(shown as black ab) initiates activation of Src, RhoA, and Rac-1, as well as
increased cytosolic free calcium ion. Phosphorylation of cortactin by Src
stimulates F-actin rearrangements in the cortical cytoplasm, which facili-
tates more ICAM-1 clustering. B: These signals lead to activation of MLCK,
inactivation of PP1c, and phosphorylation of VE-cadherin, inducing release
of the associated catenins. C: Leukocyte PECAM engagement of endothelial
cell PECAM and/or other leukocyteeendothelial cell interactions at the
apical surface of the endothelial border activate kinesin molecular motors
in the endothelial cell and stimulate targeted trafﬁcking of LBRC membrane
to the vicinity of the leukocyte. D: Targeted trafﬁcking of LBRC membrane
continues as the leukocyte moves into the border between endothelial
cells, now enlarged by the contribution of membrane from the LBRC. This
process continues until transmigration is complete. Circled P, phosphory-
lated state; ROS, reactive oxygen species. Reproduced from Muller5 with
permission of Annual Reviews.
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MullerPECAM-deﬁcient ECV-304 cells imparts the ability to sup-
port transmigration in a manner that could be blocked by anti-
PECAM.48 Interestingly, at baseline these cells express
ICAM-1 and CD99; however, in the absence of PECAM, this
is not sufﬁcient to support transmigration.48
Where these molecules exert their control over TEM and
how they relate to PECAM, CD99, and the LBRC are
questions for future research. In fact, how all of the mecha-
nisms discussed in this section relate to each other is not
known. Do they occur sequentially? Is there a hierarchy? One
consideration is that inﬂammation, although a stereotyped
response, is not identical at all times and in all places.
Depending on the stimulus, the vascular bed, and the timing,
different leukocyte types and mechanisms may predominate.
However, considering that during diapedesis the leading edge
of the leukocyte is under the endothelial cell interacting with
the basement membrane while the trailing uropod is still on
the apical surface, it is likely that many of these molecular
interactions and mechanisms occur simultaneously in
different parts of the endothelial cell and leukocyte.Frontiers and Future Directions
Isolating the LBRC
Signiﬁcant progress has been achieved in our understanding
of the TEM process. However, as with all important sci-
entiﬁc problems, the answers to one question lead to even
more questions. How is the LBRC formed, and what is it
composed of? We are taking two approaches to answering
these questions. Homogenization and subcellular fraction-
ation of endothelial cells on sucrose density gradients is
yielding some important information. David Sullivan in my
research group (unpublished data) took advantage of the fact
that the LBRC is accessible by antibodies at 37C but not at
4C to bind HRPeconjugated antibody to PECAM on the
surface of the cell border but not in the LBRC. After ho-
mogenization and ﬂotation away from contaminating or-
ganelles, membrane vesicles were brieﬂy exposed to 3,30-
diaminobenzidine (DAB) and H2O2. In vesicles containing
membrane from the endothelial cell surface, the HRP892oxidizes DAB to insoluble multimers that precipitate on the
membrane and increase the density of the vesicles con-
taining them. On the other hand, vesicles of LBRC do not
contain HRPelabeled antibody and consequently are
considerably less dense than the vesicles containing surface
membrane. The spectrum of proteins seen is compared to
that seen when both surface and LBRC are labeled. This
variation of the DAB density shift87,88 is being used to
purify LBRC membrane and analyze it for novel LBRC-
associated proteins. Dr. Sullivan has found an unsuspected
cytosolic protein associated with the LBRC that appears to
play a major role in its targeted recycling (unpublished
data).
What Directs Molecules Into and Out of the LBRC?
We have previously demonstrated that mutation of tyrosine
663 on the cytoplasmic tail of PECAM blocks TEM without
affecting classic PECAM signaling.60 We found that this
mutation interfered with the ability of PECAM to enter and
leave the LBRC. This suggests that Y663 might be a part of
a localization signal that allows PECAM to trafﬁc into the
LBRC. Dr. Gong Feng in my research group has been
making chimeric molecules in which the extracellular and
cytoplasmic domains of molecules known to be included in
the LBRC (eg, PECAM) and those known to be excluded
from the LBRC (eg, VE-cadherin) are swapped to determine
the rules for sorting of molecules into the LBRC (unpub-
lished data).
The Minimal Machinery Necessary for TEM
Interest in transcellular migration of leukocytes has been far
greater than its physiological presence might suggest. Direct
in vivo measurements show that polymorphonuclear leu-
kocytes migrate transcellularly less than 10% of the time.10
Nonetheless, we are interested in this phenomenon because
it could allow us to understand the mechanisms necessary
for transmigration itself, without the potential confounding
factors related to junctional integrity. Drs. Annette Gonzalez
and Alexei Mikhailov have been studying this process usingFigure 4 The experimental logic for deter-
mining the relationship of VE-cadherin gap for-
mation and targeted recycling (TR) of the LBRC.
The two independent experiments yield four
possible results. However, only one of the four
proposed relationships is consistent with suc-
cessful completion of both experiments A and B.
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Regulation of Transendothelial Migrationhuman umbilical vein endothelial cells (HUVECs) in which
the endogenous PECAM has been replaced by PECAM-
eGFP. Studying monocyteeendothelial cell interactions by
live-cell imaging, they have found that leukocytes tightly
adherent to the apical surface of the endothelial cells attract
a cloud of ﬂuorescent PECAM-bearing membrane (pre-
sumably the LBRC, as in ref. 45) that follows them as they
locomote along the apical surface. When a monocyte
transmigrates, the cloud coalesces into a ring that tightly
surrounds the leukocyte as it migrates through the endo-
thelial cell, contracts as the uropod vanishes beneath the
endothelial cell, and dissipates after transcellular migration.
Presumably, the membrane reverts to interconnected tubu-
lovesicular structures and relocalizes to the perijunctional
zone, but optical limitations preclude direct observation.
Which molecular motors and adaptor proteins are
responsible for moving the LBRC toward the leukocyte and
recovering it after TEM? Bita Cyrus in my research group is
studying these questions using a combination of biochem-
ical, microinjection, and knockdown strategies.
The Plasticity of Endothelial Junctions
One of the difﬁculties limiting study of the mechanisms of
transcellular migration is that even under the most condu-
cive circumstances only approximately 30% of poly-
morphonuclear leukocytes and approximately 10% of
monocytes migrate transcellularly. It has been postulated
that transcellular migration occurs more frequently at the
bloodebrain barrier, where true tight junctions exist and
paracellular migration would be expected to be particularly
difﬁcult.58,89 To study the mechanisms of transcellular TEM
in a robust system, Ryan Winger in my research group has
developed ways to make the endothelial cell borders tighter.
Using a combination of methods reported in the literature to
decrease junctional permeability, he has been able to
routinely grow endothelial cell monolayers with trans-
endothelial electrical resistances of 250 U$cm2, which is as
high as has been reported in vitro with human cells.34,35,90
In preliminary experiments, however, transmigration rates
of monocytes are not diminished, transmigration is still
PECAM and CD99 dependent, and, surprisingly, 99% of
the transmigration events are paracellular. Data show the
remarkable plasticity of the endothelial junctions, because
during TEM the electrical resistance does not decrease.
The Relationship of LBRC and VE-Cadherin Movements
How are the movements of the LBRC and VE-cadherin
coordinated? During TEM, VE-cadherin is removed from the
cell border at the site of transmigration, whereas the LBRC
moves in.67,68 VE-cadherin gap formation can be prevented
by mutations in the cytoplasmic tail of VE-cadherin that
prevent it from interacting with b-catenin and p120.72 Just
like targeted recycling of the LBRC, VE-cadherin gap for-
mation is required for TEM, and manipulations that inhibitThe American Journal of Pathology - ajp.amjpathol.orggap formation also reduce TEM. Does VE-cadherin leave
ﬁrst and then the LBRC moves in to ﬁll this vacuum? Does
the LBRC move in and push VE-cadherin out of the way?
Are these two movements of membrane somehow coordi-
nated or cooperative? Or are they totally independent? Dr.
Annette Gonzalez is approaching this problem using a series
of experiments in which she selectively blocks either targeted
recycling or VE-cadherin gap formation and determines the
effect on the other membrane compartment. The results of
these experiments should unambiguously determine the
relationship of these events, both of which are essential for
TEM (Figure 4).
Other Challenges
We have known for more than 20 years that a transient
increase in cytosolic free calcium ion concentration64 is
required for TEM. However, we still do not know which
step or steps in transmigration are regulated by the calcium
ﬂux. Evan Weber, a student in my research group, is
working on this problem using an in vitro TEM assay that
can dissect the contributions of adhesion, locomotion, dia-
pedesis, and migration across the basement membrane91 to
the leukocyte extravasation process. The role of CD99 in
TEM was ﬁrst demonstrated more than a decade ago, but
CD99 is a unique molecule with no homologs in the genome
(other than the somewhat distantly related paralog
CD99L292) and no known signaling motifs on its cyto-
plasmic tail.22 Understanding its mechanism of action has
therefore been a challenge. Richard Watson, another student
in my research group, has been studying signaling events
that can overcome a CD99 blockade to transmigration and is
tracing these pathways back to CD99.
Several other unanswered questions remain. How is it that
the molecules that regulate TEM are all present together in
the LBRC, yet PECAM, CD155, and CD99 act sequentially?
Why are there so many molecules on leukocytes and endo-
thelial cells that, when blocked with antibodies or knocked
down or out, have such a large effect on TEM? If interfering
with the function of any one of them blocks TEM by more
than 50%, then the others should act in a common step
(otherwise, it would easily be possible to block 100% of
TEM, which is never seen). What is that common step? Why
don’t the other molecules compensate for the one molecule
that has been deleted or inhibited in these studies? When we
fully understand the mechanisms of TEM, we will have the
answers to such questions and will, we hope, have a much
better handle on controlling the inﬂammatory response.Acknowledgments
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